Blogs about Biotechnology, Pharmaceutical and Healthcare

10:21 EDT 28th April 2015 | BioPortfolio

Read the latest opinions - blogs from pharmaceutical and life science industry experts.

Showing News Articles 1–25 of 39,000+

Tuesday 28th April 2015

Healthy volunteer controls wanted by UK ME/CFS Biobank | 28 April 2015

Volunteers can be seen in either Norwich or London.

Intercept Pharmaceuticals: Serving Unmet Needs With Blockbuster Potential

Will Pfizer Relaunch Its AstraZeneca Bid?

Why ANI Pharmaceuticals Should Significantly Outperform Expectations In 2015

Catalent: A Core Position Candidate?

United Therapeutics (UTHR) Q1 2015 Results - Earnings Call Webcast

Looking At Biogen Through Warren Buffett's Eyes

After Failure Of Phase 3 Trial, Aerie Pharmaceuticals Struggles To Find Value

Civitas Solutions: Addressing Its At-Risk Youth Issues Is Bullish Longer-Term

Taro's Stock Has An Upside Potential

Hard Day's Night for Biotech Investors

We first posted our thoughts on the upcoming biotech correction and updated it by characterizing the upcoming series of micro-booms and bursts.We haven't changed and we'll underscore our prior thoughts.If you have a developed a thoughtful routine for dealing with white swan and black swan events, so much the better. The biotech area has more than its fair share of volatility.Lastly, try to learn s...

Centene (CNC) Q1 2015 Results - Earnings Call Webcast

IDEXX Laboratories (IDXX) Q1 2015 Results - Earnings Call Webcast

Gilead Sciences' Rumored Takeover Of Vertex Pharmaceuticals Has Merit

Aetna (AET) Q1 2015 Results - Earnings Call Webcast

Boston Scientific (BSX) Q1 2015 Results - Earnings Call Webcast

Merck & Co (MRK) Q1 2015 Results - Earnings Call Webcast

With 3 Near-Term Catalysts And Heavy Insider Buying, This Biotech Should Be In Your Portfolio Now

CR Bard's Buyback Report Card

Study: Mental Health Effects Of Bullying Even Worse Than Effects Of Abuse By Adults

According to a new study, those bullied by peers often suffer even worse long-term mental health outcomes than those maltreated by adults early in life. The effects of both sorts of abuse are well-documented, but this is the first study to examine wh...

Why Baltimore Burned

Do you know why Baltimore burned on Monday? The real culprit: Persistent inequality that puts people down -- and keeps them down.

Celgene acquires Quanticel Pharmaceuticals

Celgene and Quanticel Pharmaceuticals announced a definitive share purchase agreement under which Celgene will acquire Quanticel. Through the agreement, Celgene will have full access to Quanticel’s proprietary platform for the single-cell genomic analysis of human cancer, as well as Quanticel’s lead programs that target specific epigenetic modifiers to advance Celgene’s pipeline of innovativ...

AstraZeneca and Innate Pharma in IPH2201 deal

Innate Pharma has signed a co-development and commercialization agreement with AstraZeneca, along with MedImmune, to accelerate and broaden the development of Innate Pharma's proprietary anti-NKG2A antibody, IPH2201, including in combination with MEDI4736, an anti-PD-L1 immune checkpoint inhibitor developed by MedImmune. Currently in Phase II development, IPH2201 is a potential first-in-class huma...

Celgene and AstraZeneca in MEDI4736 pact

Celgene has entered into a strategic collaboration with MedImmune to develop and commercialize an anti-PD-L1 inhibitor, MEDI4736, for hematologic malignancies. MEDI4736 is a human monoclonal antibody directed against programmed cell death ligand 1 (PD-L1), which helps tumors avoid detection by the immune system. Tumor cells use PD-L1 to turn off the immune system just as more » The post Celgene a...

Jounce Therapeutics gains series B financing for $56 million

Jounce Therapeutics announced the successful completion of a $56 million oversubscribed Series B financing. Proceeds from the financing will be used to advance Jounce’s pipeline of cancer immunotherapy programs, including moving its lead program directed at Inducible T cell Co-stimulator (ICOS) into clinical testing, as well as advancing a second program through IND-enabling studies. Searching m...

Search BioPortfolio: